Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK
Clinical and Molecular Hepatology · 2024
DOI: 10.3350/cmh.2024.0203 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Molecular Hepatology, 2024. Verfasst von Kwanjoo Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: COVID-19, Gastrointestinal Diseases, SARS-CoV-2, Liver Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Institute for Information & Communications Technology Planning & Evaluation.
Abstract (Originalsprache)
Background/Aims: Considering emerging evidence on long COVID, comprehensive analyses of the post-acute complications of SARS-CoV-2 infection in the gastrointestinal and hepatobiliary systems are needed. We aimed to investigate the impact of COVID-19 on the long-term risk of gastrointestinal and hepatobiliary diseases and other digestive abnormalities.
Methods
We used three large-scale population-based cohorts: the Korean cohort (discovery cohort), the Japanese cohort (validation cohort-A), and the UK Biobank (validation cohort-B). A total of 10,027,506 Korean, 12,218,680 Japanese, and 468,617 UK patients aged ≥20 years who had SARS-CoV-2 infection between 2020 and 2021 were matched to non-infected controls. Seventeen gastrointestinal and eight hepatobiliary outcomes as well as nine other digestive abnormalities following SARS-CoV-2 infection were identified and compared with controls.
Results
The discovery cohort revealed heightened risks of gastrointestinal diseases (HR 1.15; 95% CI 1.08–1.22), hepatobiliary diseases (HR 1.30; 95% CI 1.09–1.55), and other digestive abnormalities (HR 1.05; 95% CI 1.01–1.10) beyond the first 30 days of infection, after exposure-driven propensity score-matching. The risk was pronounced according to the COVID-19 severity. The SARS-CoV-2 vaccination was found to lower the risk of gastrointestinal diseases but did not affect hepatobiliary diseases and other digestive disorders. The results derived from validation cohorts were consistent. The risk profile was most pronounced during the initial 3 months; however, it persisted for >6 months in validation cohorts, but not in the discovery cohort.
Conclusions
The incidence of gastrointestinal disease, hepatobiliary disease, and other digestive abnormalities increased in patients with SARS-CoV-2 infection during the post-acute phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
- Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, Korea.
- Department of Regulatory Science, Kyung Hee University, Seoul, Korea.
- Department of Biomedical Engineering, Kyung Hee University, Yongin, Korea.
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
- Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Institute for Information & Communications Technology Planning & Evaluation
Zitieren
APA
Lee, K., Park, J., Lee, J., Lee, M., Kim, H. J., Son, Y., Rhee, S. Y., Smith, L., Rahmati, M., Kang, J., Lee, H., Ha, Y., & Yon, D. K. (2024). Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0203
Vancouver
Lee K, Park J, Lee J, Lee M, Kim HJ, Son Y, et al. Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK. Clinical and Molecular Hepatology. 2024. doi:10.3350/cmh.2024.0203
BibTeX
@article{Lee2024,
author = {Lee, Kwanjoo and Park, Jaeyu and Lee, Jinseok and Lee, Myeongcheol and Kim, Hyeon Jin and Son, Yejun and Rhee, Sang Youl and Smith, Lee and Rahmati, Masoud and Kang, Jiseung and Lee, Hayeon and Ha, Yeonjung and Yon, Dong Keon},
title = {Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK},
journal = {Clinical and Molecular Hepatology},
year = {2024},
doi = {10.3350/cmh.2024.0203}
}
EUVIMED